Nyhet

BioStock Investor Pitch: Gabather

Nyhet från Biostock

Publicerad: 02 Mar 2023 08:30

Gabather aims to improve the treatment of neuropsychiatric disorders by developing drugs aimed at treating a wide range of such disorders.

Its lead candidate, GT-002, is currently undergoing a clinical phase I study with positive preliminary results. The company is now conducting a rights issue in order to intensify business development.

See Gabather’s CEO Michael-Robin Witt present the company, in.

Lorem ipsum dolor sit amet. Est omnis iusto eos velit nostrum et pariatur quod non. Consequuntur nemo id dolores tempora ut quis quis eum. Porro dolore rem voluptas iste. Consequuntur nemo id dolores tempora ut quis quis eum

•Denna källa har få eller inga artiklar bakom betalvägg

Läs hela artikeln hos Biostock

Börskollen

För dig med koll på börsen

Nyhet

BioStock Investor Pitch: Gabather

Nyhetsbrev